Prognostic Nutritional Index (PNI) and Its Impact on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Retrospective Cohort Study in China 标题:预后营养指数(PNI)及其对异体造血干细胞移植患者预后的...
Elderly patients with AML are less tolerant to high-intensity consolidation therapy than younger patients, with significantly worse prognoses. Induction and consolidation therapy combined with allogeneic hematopoietic stem cell microtransplantation may improve the prognosis of elderly patients with AML. The ...
CH-MDS-AML demonstrated a predominance of elderly and male cases, cytopenia, and significantly adverse clinical outcomes. Besides, gene expression networks including HOXA/B, platelet factors, and inflammatory responses were most ...
Prognosis of acute myeloid leukemia (AML) patients depends on patient-related features, disease manifestations at the time of presentation, and intrinsic disease-related genetic features, such as cytogenetic abnormalities and driver mutations. Prognostic
Despite development of immunophenotyping- and cytogenetic -based prognostic biomarkers, AML remains a disease with a highly variable prognosis and a high mortality rate. Less than 50% of patients survive for 5 years overall, and only 20% of elderly patients survive to 2 years after diagnosis (Pra...
In general, AML prognosis is broadly stratified based on patient age. Patients 60 years old or younger have a 35–40 % chance of achieving a cure while those older than 60 have only a 5–15 % chance [2]. Yet, AML prevalence is much more common among the elderly with a median age ...
Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017;18:112–21. Duy C, Li M, Teater M, Meydan C, Garrett-Bakelman FE, Lee TC, ...
To further determine whether miR-182 promoter methylation is a predictive biomarker for AZA + VEN response in a clinical setting, we investigated the methylation frequency of miR-182 promoter in 94 AZA + VEN-treated elderly or unfit AML patients....
associated with poorer overall survival, especially among those with intermediate-risk cytogenetics [107]. TheDNMT3AR882mutations are associated with poorer prognosis in older patients, whereas non-R882DNMT3Amutations are associated with poorer prognosis in younger patients [108]. Numerous studies show...
TP53 mutation has been associated with a poor prognosis in both AML and MDS [58, 59]. A recent study analyzed 3,324 patients with MDS for TP53 mutations and allelic imbalances, and delineated two subsets of patients with distinct phenotypes and outcomes. One-third of TP53-mutated patients ...